vs
BRADY CORP（BRC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
BRADY CORP的季度营收约是Orthofix Medical Inc.的1.8倍（$405.3M vs $219.9M），BRADY CORP净利率更高（13.3% vs -1.0%，领先14.3%），BRADY CORP同比增速更快（7.5% vs 2.0%），BRADY CORP自由现金流更多（$22.4M vs $16.8M），过去两年BRADY CORP的营收复合增速更高（12.1% vs 8.0%）
布雷迪公司是美国特种产品、技术设备及标识解决方案供应商，1914年创立，总部位于威斯康星州密尔沃基，在美洲、欧洲、亚洲、澳洲拥有6600名员工，业务覆盖全球，为各行业客户提供工作场景所需的零部件标识相关产品与服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BRC vs OFIX — 直观对比
营收规模更大
BRC
是对方的1.8倍
$219.9M
营收增速更快
BRC
高出5.5%
2.0%
净利率更高
BRC
高出14.3%
-1.0%
自由现金流更多
BRC
多$5.6M
$16.8M
两年增速更快
BRC
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $405.3M | $219.9M |
| 净利润 | $53.9M | $-2.2M |
| 毛利率 | 51.5% | 71.1% |
| 营业利润率 | 16.8% | 0.2% |
| 净利率 | 13.3% | -1.0% |
| 营收同比 | 7.5% | 2.0% |
| 净利润同比 | 15.3% | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRCOFIX
| Q4 25 | $405.3M | $219.9M | ||
| Q3 25 | $397.3M | $205.6M | ||
| Q2 25 | $382.6M | $203.1M | ||
| Q1 25 | $356.7M | $193.6M | ||
| Q4 24 | $377.1M | $215.7M | ||
| Q3 24 | $343.4M | $196.6M | ||
| Q2 24 | $343.4M | $198.6M | ||
| Q1 24 | $322.6M | $188.6M |
净利润BRCOFIX
| Q4 25 | $53.9M | $-2.2M | ||
| Q3 25 | $49.9M | $-22.8M | ||
| Q2 25 | $52.3M | $-14.1M | ||
| Q1 25 | $40.3M | $-53.1M | ||
| Q4 24 | $46.8M | $-29.1M | ||
| Q3 24 | $55.5M | $-27.4M | ||
| Q2 24 | $50.9M | $-33.4M | ||
| Q1 24 | $43.6M | $-36.0M |
毛利率BRCOFIX
| Q4 25 | 51.5% | 71.1% | ||
| Q3 25 | 50.4% | 72.2% | ||
| Q2 25 | 51.0% | 68.7% | ||
| Q1 25 | 49.3% | 62.8% | ||
| Q4 24 | 50.3% | 69.0% | ||
| Q3 24 | 51.6% | 68.7% | ||
| Q2 24 | 51.6% | 67.8% | ||
| Q1 24 | 50.2% | 67.5% |
营业利润率BRCOFIX
| Q4 25 | 16.8% | 0.2% | ||
| Q3 25 | 14.9% | -8.3% | ||
| Q2 25 | 17.6% | -7.9% | ||
| Q1 25 | 14.4% | -25.2% | ||
| Q4 24 | 15.6% | -5.3% | ||
| Q3 24 | 19.3% | -9.6% | ||
| Q2 24 | 18.5% | -12.5% | ||
| Q1 24 | 16.7% | -15.6% |
净利率BRCOFIX
| Q4 25 | 13.3% | -1.0% | ||
| Q3 25 | 12.6% | -11.1% | ||
| Q2 25 | 13.7% | -6.9% | ||
| Q1 25 | 11.3% | -27.4% | ||
| Q4 24 | 12.4% | -13.5% | ||
| Q3 24 | 16.1% | -13.9% | ||
| Q2 24 | 14.8% | -16.8% | ||
| Q1 24 | 13.5% | -19.1% |
每股收益（稀释后）BRCOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $182.7M | $82.0M |
| 总债务越低越好 | $115.9M | — |
| 股东权益账面价值 | $1.2B | $450.0M |
| 总资产 | $1.8B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资BRCOFIX
| Q4 25 | $182.7M | $82.0M | ||
| Q3 25 | $174.3M | $62.9M | ||
| Q2 25 | $152.2M | $65.6M | ||
| Q1 25 | $138.5M | $58.0M | ||
| Q4 24 | $145.7M | $83.2M | ||
| Q3 24 | $250.1M | $30.1M | ||
| Q2 24 | $160.5M | $26.4M | ||
| Q1 24 | $143.9M | $27.0M |
总债务BRCOFIX
| Q4 25 | $115.9M | — | ||
| Q3 25 | $99.8M | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | $90.9M | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益BRCOFIX
| Q4 25 | $1.2B | $450.0M | ||
| Q3 25 | $1.2B | $442.5M | ||
| Q2 25 | $1.2B | $458.3M | ||
| Q1 25 | $1.1B | $458.3M | ||
| Q4 24 | $1.1B | $503.1M | ||
| Q3 24 | $1.1B | $525.9M | ||
| Q2 24 | $1.0B | $546.0M | ||
| Q1 24 | $1.0B | $570.3M |
总资产BRCOFIX
| Q4 25 | $1.8B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.7B | $837.2M | ||
| Q1 25 | $1.6B | $823.1M | ||
| Q4 24 | $1.6B | $893.3M | ||
| Q3 24 | $1.5B | $867.9M | ||
| Q2 24 | $1.4B | $882.0M | ||
| Q1 24 | $1.4B | $906.0M |
负债/权益比BRCOFIX
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.08× | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | 0.09× | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $22.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 5.5% | 7.6% |
| 资本支出强度资本支出/营收 | 2.7% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.62× | — |
| 过去12个月自由现金流最近4个季度 | $159.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BRCOFIX
| Q4 25 | $33.4M | $27.7M | ||
| Q3 25 | $58.3M | $12.4M | ||
| Q2 25 | $59.9M | $11.6M | ||
| Q1 25 | $39.6M | $-18.4M | ||
| Q4 24 | $23.4M | $23.7M | ||
| Q3 24 | $84.0M | $11.7M | ||
| Q2 24 | $72.7M | $9.0M | ||
| Q1 24 | $36.1M | $-18.6M |
自由现金流BRCOFIX
| Q4 25 | $22.4M | $16.8M | ||
| Q3 25 | $49.4M | $2.5M | ||
| Q2 25 | $55.6M | $4.5M | ||
| Q1 25 | $32.5M | $-25.1M | ||
| Q4 24 | $16.1M | $15.2M | ||
| Q3 24 | $73.2M | $6.3M | ||
| Q2 24 | $64.4M | $-360.0K | ||
| Q1 24 | $-13.5M | $-29.1M |
自由现金流率BRCOFIX
| Q4 25 | 5.5% | 7.6% | ||
| Q3 25 | 12.4% | 1.2% | ||
| Q2 25 | 14.5% | 2.2% | ||
| Q1 25 | 9.1% | -13.0% | ||
| Q4 24 | 4.3% | 7.0% | ||
| Q3 24 | 21.3% | 3.2% | ||
| Q2 24 | 18.8% | -0.2% | ||
| Q1 24 | -4.2% | -15.4% |
资本支出强度BRCOFIX
| Q4 25 | 2.7% | 4.9% | ||
| Q3 25 | 2.2% | 4.8% | ||
| Q2 25 | 1.1% | 3.5% | ||
| Q1 25 | 2.0% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 3.1% | 2.7% | ||
| Q2 24 | 2.4% | 4.7% | ||
| Q1 24 | 15.4% | 5.6% |
现金转化率BRCOFIX
| Q4 25 | 0.62× | — | ||
| Q3 25 | 1.17× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 0.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRC
| Americas Asia | $215.1M | 53% |
| Europe Australia | $119.9M | 30% |
| Other | $70.2M | 17% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
